3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Recurrence
2
Squamous Cell Carcinoma of Head and Neck
1
Rhabdomyosarcoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Leiomyosarcoma
1
Hodgkin Disease
1
Interventions
Cisplatin
168
Radiotherapy
110
pembrolizumab
96
Cetuximab
95
Docetaxel
74
Carboplatin
74
Radiotherapy, Intensity-Modulated
55
Paclitaxel
51
Nivolumab
50
Fluorouracil
47
Surgical Procedures, Operative
28
Radiation
26
Magnetic Resonance Spectroscopy
25
durvalumab
23
Drug Therapy
23
Radiosurgery
21
Biopsy
19
Albumin-Bound Paclitaxel
19
130-nm albumin-bound paclitaxel
18
Taxes
17
tislelizumab
16
toripalimab
15
Chemoradiotherapy
15
Neoadjuvant Therapy
14
Erlotinib Hydrochloride
14
Blood Specimen Collection
14
camrelizumab
13
Immunohistochemistry
13
Specimen Handling
12
tremelimumab
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Squamous Cell Carcinoma of Head and Neck
×
mocetinostat
×
Clear all
NCT02993991
2017-12-29
PRIMED-001
University Health Network, Toronto
Phase 1
Withdrawn